Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
- 83 Downloads
The US Food and Drug Administration (FDA) is encouraging the innovation of long-acting opioid formulations that are manipulation-resistant. The purpose of this commentary is to assess the benefits and limitations of abuse-deterrent opioid formulations (ADFs) and discuss their role in mitigating the current opioid epidemic. ADFs have been created with chemical properties that make it difficult for people who non-medically use prescription drugs to crush and dissolve opioid tablets, as well as by combining opioids with antagonists such as naloxone or naltrexone, which are released only when the dosage form has been manipulated or the drug is taken by a non-intended route. Despite these and other technologies, consensus regarding the effectiveness of these formulations in preventing non-medical use is lacking given the difficulty in obtaining post-marketing data. Researchers also question if the creation of abuse-deterrent drugs will have a positive effect on those struggling with a severe opioid-use disorder, fearing that current opioid users will simply find a new – perhaps more dangerous – drug of choice. Abuse-deterrent opioids are still opioids, and although they may make manipulation more difficult than non-ADF formulations, they are not “abuse proof.” The introduction of ADFs could provide a false sense of security among prescribers and dispensers, and we fear that ADFs may have a minimal impact on non-medical use of prescription opioids. Further epidemiological studies will be required to determine the large-scale impact of abuse-deterrent opioids in preventing opioid use disorder and its downstream consequences.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
The authors declare that no sources of funding were used to prepare this article.
- 1.Throckmorton DC. Presentation: FDA Perspective on Abuse-Deterrent Opioid Development. 2017. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM545923.pdf. Accessed 20 Dec 2017.
- 4.Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287–96. https://doi.org/10.1016/j.pain.2013.05.053.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.U.S. Food and Drug Administration. Abuse-Deterrent Opioids. 2017. https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337066.htm. Accessed Dec 18 2017.
- 6.U.S. Food and Drug Administration. Guidance for Industry. 2015. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed Dec 13 2017.
- 8.Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clinic Proc. 2012;87(7):683–94. https://doi.org/10.1016/j.mayocp.2012.02.022.CrossRefGoogle Scholar
- 11.Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11(4):303–11. https://doi.org/10.1016/j.jpain.2009.07.017.CrossRefPubMedGoogle Scholar
- 23.Centers for Disease Control and Prevention. HIV and Injection Drug Use. 2016. https://www.cdc.gov/vitalsigns/hiv-drug-use/index.html. Accessed 20 Dec 2017.
- 28.Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–74. https://doi.org/10.1146/annurev-publhealth-031914-122957.CrossRefPubMedGoogle Scholar
- 29.Twillman R, Fudin J. Potential cost-shifting and hidden costs and risks in the economic analysis of opioid abuse-deterrent formulations. Pain Med (Malden, Mass). 2014;15(9):1447–9. https://doi.org/10.1111/pme.12500.
- 31.Good CB. Presentation: Abuse-Deterrent Opioid Formulations. 2016. https://www.fda.gov/downloads/Drugs/NewsEvents/UCM527924.pdf. Accessed 20 Dec 2017.
- 32.Joranson DE, Gilson AM. Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage. vol 4. United States 2005. p. 299–301.Google Scholar
- 33.Substance Abuse and Mental Health Services Administration. Results from the 2015 National Survey on Drug Use and Health: Detailed Tables. 2016. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.htm. Accessed 20 Dec 2017.